Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma

Eur Urol. 2009 Jun;55(6):1477-80. doi: 10.1016/j.eururo.2008.12.036. Epub 2009 Jan 9.

Abstract

The authors present the first case report of complete histologic remission after neoadjuvant sunitinib treatment on primary renal tumour and vena cava thrombus. A 78-yr-old woman with an Eastern Cooperative Oncology Group (ECOG) score of 0 presented with a T3b renal tumour. She refused surgical treatment but agreed to percutaneous biopsy and medical treatment. A Fuhrman III renal cell carcinoma was histologically confirmed on percutaneous biopsy, and sunitinib treatment was administered over 6 mo. A significant objective response was observed for tumour size and thrombus. The patient finally accepted surgical treatment. Pathologic examination concluded with a complete response of primary tumour and thrombus.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Biopsy, Needle
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / pathology*
  • Carcinoma, Renal Cell / surgery
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Indoles / therapeutic use*
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology*
  • Kidney Neoplasms / surgery
  • Magnetic Resonance Imaging
  • Neoadjuvant Therapy*
  • Neoplasm Staging
  • Nephrectomy / methods
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrroles / therapeutic use*
  • Sunitinib
  • Treatment Outcome

Substances

  • Indoles
  • Protein Kinase Inhibitors
  • Pyrroles
  • Sunitinib